Compound profile

DSIP

The delta sleep-inducing peptide, explained honestly

What DSIP is, why its mechanism is still called a riddle, the gap between its trial doses and community dosing, what the small human studies show, and why the FDA panel treated it differently.

How it works

The mechanism

Named for deep sleep, but its actual biology is still being argued over.

Born from sleep research

First isolated in the 1970s from the blood of sleep-deprived rabbits and named for its link to delta-wave, or slow-wave, sleep.

A still-unresolved riddle

A 2006 review used exactly that phrase. Proposed actions touch serotonin, dopamine, glutamate and melatonin, but none are settled.

A stress-axis angle

It is also studied for effects on the hypothalamic-pituitary-adrenal axis, which is the basis for interest in cortisol regulation.

The honest read

Why DSIP is interesting, and why it is uncertain

A genuinely intriguing idea, held back by thin and inconsistent evidence.

What draws interest

A natural sleep signal

It came out of real sleep research, is tied to slow-wave sleep rather than sedation, and has a plausible stress-and-cortisol angle that fits how people want to use it.

Appeal: non-sedating sleep and stress support

Why it is uncertain

Thin, mixed data

Human trials are small and inconsistent, the mechanism is unresolved, and the FDA panel uniquely voted against a compounding pathway for it.

Reality: under-studied, not proven

Study by study: DSIP human studies.

Evidence

What the research shows

A handful of old human studies and a mechanism that never fully resolved.

Healthy human sleep
Modestacute and delayed effects

An early controlled study looked at DSIP's acute and delayed effects on human sleep behavior. Signals were present but small, using IV infusion.

Schneider-Helmert, sleep study 1982 (PMID 6895513)

Chronic insomniacs
Short-termsleep on brief dosing

A study of short-term DSIP administration in chronic insomniacs reported improvement in sleep measures, again from a small, dated trial.

Insomnia trial, 1987 (PMID 3583493)

Mechanism review
Unresolveddecades on, still unclear

A 2006 review surveyed the field and concluded DSIP remained a still unresolved riddle, which is a fair summary of the evidence today.

Kovalzon & Strekalova 2006 (PMID 16539679)

The full breakdown: DSIP human studies.

Dosing

How it is dosed

The trial doses and the community doses are not the same thing, and it is worth keeping them apart.

Early human trials
25 nmol/kg IV infusion

Precise intravenous infusions in a supervised clinical setting, timed to measure acute sleep pressure.

Research-community convention
100–300mcg nightly

Subcutaneous, before sleep. Not validated in any controlled trial, so treat it as an unverified community figure.

Educational information, not medical advice; dosing should come from a prescriber. Check your math with the dosage calculator.

Safety

Side effects

Little was reported in the old trials, but that is partly because so little has been studied.

  • Injection site: pain or redness where it is injected is the main practical effect.
  • Next-day grogginess: occasionally reported anecdotally, though not well documented in trials.
  • Unknown: long-term safety is essentially uncharacterized given how few and how old the studies are.
  • Source quality: research-grade material is not tested for identity, purity or sterility.

Caution: the thin evidence base cuts both ways, there is no strong signal of harm and no strong signal of benefit. If sleep is the goal, proven approaches should come first. Talk to a provider.

A fit man in his thirties asleep and peaceful in a dark, calm bedroom with soft moonlight
Legal status

DSIP's legal status in 2026

Panel voted against

On July 24, 2026 the FDA advisory committee voted 7 to 6 against adding DSIP (emideltide) to the 503A list, the only one of seven peptides reviewed that day to be rejected.

Not FDA-approved

DSIP is not FDA-approved, not on the 503A list, and was not included in the October 2026 HHS compounding policy.

Research chemical

Products sold as DSIP are for laboratory use only, not for human consumption, with no compounding pathway in the US.

Updates: FDA peptide status tracker · how to get peptides legally.

Track it

Know if it's working

Sleep is highly suggestible, so a consistent log matters more here than almost anywhere else.

  • Time to fall asleep and number of wake-ups, scored each morning
  • Next-day energy and grogginess, since that is where downsides show up
  • Dose and time taken, and anything else that changed that night

A wearable's sleep estimate is a rough guide, not proof. The dashboard logs doses and nightly ratings over time.

A fit woman in her thirties checking a sleep-tracking app on her phone in bed in soft morning light

Frequently asked questions

What is DSIP?

DSIP, delta sleep-inducing peptide, is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, first isolated in the 1970s from the blood of sleep-deprived rabbits. It was named for an early association with delta-wave, or slow-wave, sleep. It is studied mainly for sleep, and also for stress and cortisol regulation, though its biology is unusually poorly understood.

How does DSIP work?

Honestly, this is one of the more mechanistically ambiguous peptides out there. A 2006 review of the literature called it a still unresolved riddle. Proposed mechanisms include modulation of somatostatin through a dopaminergic pathway, broader effects on serotonin, glutamate, dopamine and melatonin, and modulation of the hypothalamic-pituitary-adrenal stress axis, which is the basis for interest in cortisol. None of these are settled.

Is DSIP FDA-approved or legal?

DSIP is not FDA-approved and is not on the FDA's 503A compounding list. It is also the one peptide that stands apart from the others in this cluster: on July 24, 2026 the FDA's advisory committee voted 7 to 6 against adding DSIP, listed as emideltide, to the compounding list, the only one of the seven peptides reviewed that day to be rejected. It was also not included in the October 2026 HHS compounding policy. In the US it is sold only as a research chemical, for laboratory use, not for human consumption.

What is the typical DSIP dose?

There is no clinically validated human dose. The early controlled human trials used precise intravenous infusions, around 25 nmol/kg, in a supervised setting. The subcutaneous nightly figure of roughly 100 to 300mcg seen in research-community protocols has not been validated in a controlled trial and should be treated as an unverified convention. Any medical use should come from a prescriber.

Does DSIP actually improve sleep?

The human evidence is small and mixed. Some early controlled trials and a short-term study in chronic insomniacs reported effects on sleep, but the results were modest and not consistently replicated, and the compound's mechanism is still unresolved. It is better described as an interesting, under-studied sleep candidate than a proven sleep aid.

Is DSIP sedating?

It is not framed as a classic sedative. The original interest was in its link to natural slow-wave sleep and sleep regulation rather than in knocking you out the way a sleep drug does. That said, because the human data is thin and the mechanism is unclear, there is no reliable profile of how it feels or how strong any effect is.

How is DSIP different from the other peptides in this group?

Regulatory status is the clearest difference. DSIP was reviewed by the same FDA panel on the same day as Semax and Epitalon, but it was voted down while those were voted in favor. So unlike most of the cluster, DSIP has no draft compounding pathway in the US and remains research-chemical only.

Track your sleep protocol

Log doses, sleep and next-day energy in one place, and tell signal from placebo. Free.

Sources

  1. Schneider-Helmert D, et al. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1982. PMID 6895513
  2. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. 1987. PMID 3583493
  3. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006. PMID 16539679
  4. FDA Pharmacy Compounding Advisory Committee vote, July 24, 2026 (DSIP / emideltide voted 7-6 against). AJMC summary

This content is for informational purposes only and is not medical advice. DSIP is not FDA-approved in the United States, was voted against by the FDA advisory committee in July 2026, and was not included in the October 2026 HHS peptide compounding policy. Research-grade DSIP is sold for laboratory use only, not for human consumption. Always consult a qualified healthcare provider before considering any peptide protocol.